TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07601074: A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

Sponsor: Daré Bioscience, Inc. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 118 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,117,200

Rescue Site Savings

+$735,000

Unlock Full NCT07601074 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07601074 Rescue Dossier →